Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. This dual-targeting activates and ...

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma – Pivotal Phase III SUNMO study demonstrated an 11.5 ...

Lunsumio can cause serious and life-threatening neurological problems. Your healthcare provider will check you for neurologic problems during treatment with Lunsumio.

Lunsumio and Polivy are a CD20×CD3 T-cell-engaging bispecific antibody and an anti-CD79b antibody-drug conjugate (ADC), respectively. Roche global product development head and chief medical ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...